He’s only been Arena’s president and CEO for two months, but biotech vet Amit Munshi is wasting no time getting to know his new staff as the company announces…

Tesaro posted stellar Phase III results yesterday for its PARP inhibitor in ovarian cancer. But following on its good vibes have been other PARP R&D…

It was a shock result for the U.K. this morning as the public decided by a narrow margin of 52-48 to leave the European Union, in what will have a profound…

Eleven Biotherapeutics, which has valiantly (or stubbornly) carried on over the past 12 months despite a slew of major trial failures, is now, finally, nearing…

Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-…

The struggling biotech Verastem that has seen its stock nose-dive will look to a future without executive chairman Christoph Westphal and director Henri…

Sorrento Therapeutics has wrapped up a $150 million private placement, giving it money for advance its pipeline and continue its Asian partnership strategy.

Mereo, which emerged last year with £76.5 million in investment and a pipeline of assets from Novartis, has listed its stock on the AIM exchange in London.